CeriBell (NASDAQ:CBLL) Receives Consensus Recommendation of “Buy” from Analysts

CeriBell (NASDAQ:CBLL) has been given an average recommendation of “Buy” by the six research firms that are presently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have covered the stock in the last year is $32.60.

CBLL has been the subject of a number of recent research reports. William Blair began coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. started coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price objective for the company. Bank of America initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $32.00 target price on the stock. Canaccord Genuity Group lifted their price target on shares of CeriBell from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Finally, Canaccord Genuity Group started coverage on CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price target on the stock.

CeriBell Stock Up 1.0 %

CBLL stock opened at $26.98 on Wednesday. CeriBell has a one year low of $23.00 and a one year high of $32.75.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Tuesday, November 12th. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The company had revenue of $17.20 million for the quarter, compared to analyst estimates of $17.06 million. Sell-side analysts expect that CeriBell will post -2.46 EPS for the current fiscal year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.